Business Wire

Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease

Initial $75M Series A investment from founding investors Atlas Venture, LAV and venBio in April 2025, recently augmented by $37.5M Series A-1 funding led by Omega Funds, with participation from ...
The Bulletin

Horner’s last-second free throw lifts No. 5 Redmond over No. 1 Caldera

Redmond’s Jack Snyder (23) lays the ball up as Caldera’s Miles Macomber (4) defends during the game on Friday at Caldera High School. Brian Rathbone • The Bulletin In Game 5 of the 1997 NBA Finals, ...
Morningstar

Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease

Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease Initial $75M Series A ...